Biohaven pharmaceutical holding company ltd. completes enrollment in pivotal phase 2/3 alzheimer's disease clinical trial of troriluzole

Biohaven pharmaceutical holding company ltd. announced that it has completed enrollment in the t2 protect ad study, a phase 2/3 clinical trial of troriluzole in alzheimer's disease. an interim futility analysis examining standard cognitive assessments and volumetric magnetic resonance imaging (mri) is expected before the end of 2019. the t2 protect ad study is a phase 2/3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of troriluzole in patients diagnosed with alzheimer's disease of mild-to-moderate severity (mini-mental state examination scores of 14-24). patients are randomized on a 1:1 basis to receive 280 mg of troriluzole or placebo once daily for 48 weeks. alzheimer's disease is a progressive, fatal neurodegenerative dementia that accounts for 60 to 80% of dementia cases. alzheimer's disease currently has no cure. although there are fda-approved medications for symptomatic treatment, their clinical benefits are generally limited.
BHVN Ratings Summary
BHVN Quant Ranking